Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

July 6, 2020July 6, 2020

Tecentriq-Chemo Combo Ups Percentage of TNBC Patients With No Cancer at Surgery

News

When given alongside chemotherapy, Tecentriq (atezolizumab) increases the percentage of people with early triple-negative breast cancer (TNBC) who show no signs of cancer during tumor removal surgery, a Phase 3 ... Read more

June 15, 2020June 15, 2020

Ibrance Plus Endrocrine Therapy Unlikely to Stop Cancer Spread, Committee Says

News

An independent data monitoring committee (DMC) has deemed it unlikely that a combination of endocrine therapy and Pfizer’s Ibrance (palbociclib) will show benefits over standard therapy at delaying or ... Read more

May 21, 2020May 21, 2020

Gene Signature Can Predict Breast Cancer Responsiveness to New Class of Drugs, Scientists Say

News

Scientists have discovered a gene signature in certain types of breast cancer that can be used to determine the likelihood of these tumors responding to treatment with a new ... Read more

April 9, 2020April 9, 2020

Positive Results Support Early Halt to Phase 3 Trial Testing Sacituzumab Govitecan for TNBC

News

Immunomedics has halted its Phase 3 confirmatory trial of sacituzumab govitecan, due to strong evidence of its ability to delay disease progression in patients with advanced triple-negative breast cancer ... Read more

February 26, 2020February 26, 2020

New Formulation of Roche’s Perjeta-Herceptin Combo for HER2-Positive Breast Cancer Up for Possible FDA Approval

News

The U.S. Food and Drug Administration (FDA) will review Roche’s application seeking regulatory approval for a new formulation — given as a subcutaneous, or under-the-skin injection — of the ... Read more

January 2, 2020January 3, 2020

Enhertu Gets FDA Approval for Treatment of Advanced HER2-positive Breast Cancer

News

The U.S. Food and Drug Administration (FDA) approved Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with inoperable or metastatic HER2-positive breast cancer who have received at least two ... Read more

December 19, 2019January 15, 2020

FDA Grants Breakthrough Therapy Status to Tucatinib for Advanced HER2-Positive Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Seattle Genetics’ tucatinib, in combination with trastuzumab and Xeloda (capecitabine), for the treatment of patients with ... Read more

December 16, 2019

Breast Cancer Index Identifies Women Likely to Benefit From Extended Hormone Therapy, Latest Data Show

News

The Breast Cancer Index, a molecular test developed by Biotheranostics, successfully identified a group of women with hormone receptor (HR)-positive breast cancer who may benefit from long-term hormone therapy ... Read more

October 25, 2019November 11, 2019

Bempegaldesleukin-Opdivo Combo Leads to Prolonged Responses in TNBC Patients, Phase 1/2 Trial Shows

News

Bempegaldesleukin (bempeg, NKTR-214) in combination with Opdivo (nivolumab) leads to prolonged treatment responses in women with advanced or metastatic triple-negative breast cancer (TNBC), a Phase 1/2 trial shows. The ... Read more

October 21, 2019December 30, 2019

Trastuzumab Deruxtecan Gets FDA Priority Review for Metastatic HER2-Positive Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has granted priority review to the application seeking trastuzumab deruxtecan‘s (DS-8201) approval for the treatment of metastatic HER2-positive breast cancer. The agency ... Read more

Pin It on Pinterest